These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20803030)

  • 1. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma.
    Ilie MI; Hofman V; Bonnetaud C; Havet K; Lespinet-Fabre V; Coëlle C; Gavric-Tanga V; Vénissac N; Mouroux J; Hofman P
    Virchows Arch; 2010 Oct; 457(4):483-95. PubMed ID: 20803030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
    Pinter F; Papay J; Almasi A; Sapi Z; Szabo E; Kanya M; Tamasi A; Jori B; Varkondi E; Moldvay J; Szondy K; Keri G; Dominici M; Conte P; Eckhardt S; Kopper L; Schwab R; Petak I
    J Mol Diagn; 2008 Mar; 10(2):160-8. PubMed ID: 18258923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.
    Wen YH; Brogi E; Hasanovic A; Ladanyi M; Soslow RA; Chitale D; Shia J; Moreira AL
    Mod Pathol; 2013 Sep; 26(9):1197-203. PubMed ID: 23599147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method.
    Gupta R; Dastane AM; Forozan F; Riley-Portuguez A; Chung F; Lopategui J; Marchevsky AM
    Mod Pathol; 2009 Jan; 22(1):128-33. PubMed ID: 18997733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma.
    Soma S; Tsuta K; Takano T; Hatanaka Y; Yoshida A; Suzuki K; Asamura H; Tsuda H
    Pathol Res Pract; 2014 Mar; 210(3):155-60. PubMed ID: 24355440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer.
    Simone G; Mangia A; Malfettone A; Rubini V; Siciliano M; Di Benedetto A; Terrenato I; Novelli F; Mottolese M
    J Exp Clin Cancer Res; 2010 Sep; 29(1):125. PubMed ID: 20843314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
    Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
    Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features.
    El-Zammar OA; Zhang S; Katzenstein AL
    Diagn Mol Pathol; 2009 Sep; 18(3):133-7. PubMed ID: 19704257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of epidermal growth factor receptor gene status in lung adenocarcinoma.
    Li C; Sun Y; Fang Z; Han X; Fang R; Zhang Y; Pan Y; Zhang W; Ren Y; Ji H; Chen H
    J Thorac Oncol; 2011 Jun; 6(6):1016-21. PubMed ID: 21532505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
    Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
    Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.
    Gaber R; Watermann I; Kugler C; Reinmuth N; Huber RM; Schnabel PA; Vollmer E; Reck M; Goldmann T
    Diagn Pathol; 2014 Sep; 9():165. PubMed ID: 25227424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
    Hirsch FR; Varella-Garcia M; Cappuzzo F; McCoy J; Bemis L; Xavier AC; Dziadziuszko R; Gumerlock P; Chansky K; West H; Gazdar AF; Crino L; Gandara DR; Franklin WA; Bunn PA
    Ann Oncol; 2007 Apr; 18(4):752-60. PubMed ID: 17317677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas.
    Liang Z; Zhang J; Zeng X; Gao J; Wu S; Liu T
    BMC Cancer; 2010 Jul; 10():376. PubMed ID: 20637128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.